Review of Juno Therapeutics
Juno Therapeutics (JUNO) is a mid-cap stock with a market cap of ~$4.75 billion. The stock rose by 8.6%. It outperformed all of the biotech stocks. In the trailing five days, the stock rose 18.6%. Investors appear to be positive after Juno discussed its strategy, product line, and the collaboration with Celgene (CELG) at the Leerink Immuno-Oncology Roundtable on October 1, 2015. The stock closed at $47.32. It was trading above the 20-day, 50-day, and 100-day moving averages.
The above graph shows the performance of Juno, the SPDR S&P Biotech ETF (XBI), and Opko Health (OPK) on a month-over-month basis. Until September 30, 2015, Juno’s YTD (year-to-date) performance was at -22.1%. XBI’s YTD performance was at 0.14%. Stocks like Opko Health, ISIS Pharmaceuticals (ISIS), and Intercept Pharmaceuticals (ICPT) had YTD performances of -15.8%, -34.5%, and 6.3%, respectively. Juno’s best performance until September was in March 2015. It had a return of 29.3%. It announced positive results for the 2014 financial year with a year-end cash position of $474.1 million. The worst performance came in April with a return of -29.5%.
Valuation and moving averages
Juno’s PBV (price-to-book value) ratio stood at 12.86x compared to XBI’s industry average of 7.04x. This indicates that the stock is trading above the industry average. Juno closed at $47.32. It was trading above the 20-day, 50-day, and 100-day moving averages. The stock has a weight of 1.2% in XBI’s portfolio.